# IMvigor210 (NCT02951767)

> A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)

No report yet. It can be ordered.

- Drugs tested: atezolizumab
- Indication: locally advanced or metastatic urothelial bladder cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02951767
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Hoffmann-La Roche
- Conditions: Bladder Cancer
- Interventions: Atezolizumab
- Enrollment: 119
- Primary outcome: Percentage of Participants With a Confirmed Objective Response of Complete Response (CR) or Partial Response (PR) as Assessed by the Independent Review Facility (IRF) According to RECIST v1.1

## Indexed commentary on IMvigor210 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 27
- Podcasts: 5

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=imvigor210-nct02951767

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02951767", "email": "<work email>"}; the inbox owner confirms by the emailed link.